





Blood 142 (2023) 6264

The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

627.AGGRESSIVE LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

High IL-10 Expression Is Associated with Poor Prognosis in Primary Gastrointestinal Lymphoma

Lingli Wang¹, Lan Ma¹, Jinjie Gao¹, Wei Wan¹, Ping Yang¹, Mingxia Zhu¹, Fei Dong¹, Hongmei Jing, MD²

Background: Primary gastrointestinal lymphoma (PGIL) is defined as the primary malignant lymphoma of the gastrointestinal tract. The long-term prognosis and life quality of PGIL patients are influenced due to gastrointestinal complications. Cytokines have a close immunological relationship with lymphocytes, however, the relationship with serum cytokines and PGIL prognosis is still unknown.

Method: We conducted a retrospective analysis of 165 PGIL patients referred to Department of Hematology of Peking university third hospital over a 10-year period between 2012-2022, and serum cytokine detection was performed on 85 patients' peripheral blood. Serum cytokine(IL-2,IL-4,IL-6,IL-9,IL-10,TNF-a)were quantified using flow cytometer. Median follow-up time was 29 months, and 1-year progression-free survival(PFS) of total PGIL patients was 84.1%, and 3-year PFS was 67.9%. The 1-year overall survival(OS)was 90.9%, and 3-year OS was 89.2%.

Results: The median age of PGIL patients was 57-year-old, and 58.8% of them were male. The two most common pathological types were diffuse large B-Cell lymphoma (40.0%) and mucosa-associated lymphoid tissue(30.6%). Our results also showed that IL-4 level was higher in surviving PGIL patients, while IL-10 level was higher in deceased PGIL patients. There was no statistically significant difference in other serum cytokines(IL-2,IL-6,IL-9, TNF-a) between surviving and deceased PGIL patients. Survival analysis showed that the OS of patients in the low IL-10 level group was lower than that in the high IL-10 group (P=0.03) Conclusion: High IL-10 expression is associated with poor prognosis in primary gastrointestinal lymphoma

Disclosures No relevant conflicts of interest to declare.

https://doi.org/10.1182/blood-2023-181473

¹ Peking University Third Hospital, Beijing, China

²Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, China